Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500917PMID: 29999976
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1197953-54-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of brigatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during brigatinib therapy and for 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Brigatinib
CAS Registry Number
1197953-54-0
Drug Class
- Breast Feeding
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Signal Transduction Inhibitors
- Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Ceritinib.[Drugs and Lactation Database (...]Review Ceritinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Gilteritinib.[Drugs and Lactation Database (...]Review Gilteritinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ponatinib.[Drugs and Lactation Database (...]Review Ponatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Bosutinib.[Drugs and Lactation Database (...]Review Bosutinib.. Drugs and Lactation Database (LactMed®). 2006
- Corrigendum to "5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells" [Chem. Biol. Interact. 284 (2018) 24-31].[Chem Biol Interact. 2022]Corrigendum to "5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells" [Chem. Biol. Interact. 284 (2018) 24-31].Han M, Shen J, Wang L, Wang Y, Zhai X, Li Y, Liu M, Gao M, Li Z, Zuo D, et al. Chem Biol Interact. 2022 Apr 1; 356:109871. Epub 2022 Feb 28.
- Brigatinib - Drugs and Lactation Database (LactMed®)Brigatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...